XmAb20717
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for XmAb20717, covering 2024-04-29 to 2025-10-09. Get the full timeline:
Most recent: Clinical Trial Update: A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers [Phase 2]